Peringatan Keamanan

Side effects include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth, blurred vision or change in near or distant vision, and eye pain.

Physostigmine

DB00981

small molecule approved investigational

Deskripsi

A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

Struktur Molekul 2D

Berat 275.3461
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Quickly hydrolyzed by cholinesterases

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

292 Data
Dipyridamole The therapeutic efficacy of Physostigmine can be decreased when used in combination with Dipyridamole.
Ephedrine Physostigmine may increase the neuromuscular blocking activities of Ephedrine.
Bambuterol Physostigmine may increase the neuromuscular blocking activities of Bambuterol.
Clevidipine Physostigmine may increase the neuromuscular blocking activities of Clevidipine.
Sar9, Met (O2)11-Substance P Physostigmine may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.
Mirabegron Physostigmine may increase the neuromuscular blocking activities of Mirabegron.
Moxisylyte Physostigmine may increase the neuromuscular blocking activities of Moxisylyte.
Propacetamol Physostigmine may increase the neuromuscular blocking activities of Propacetamol.
Procaine Physostigmine may increase the neuromuscular blocking activities of Procaine.
Cocaine Physostigmine may increase the neuromuscular blocking activities of Cocaine.
Trimethaphan Physostigmine may increase the neuromuscular blocking activities of Trimethaphan.
Doxacurium Physostigmine may increase the neuromuscular blocking activities of Doxacurium.
Chloroprocaine Physostigmine may increase the neuromuscular blocking activities of Chloroprocaine.
Tubocurarine Physostigmine may increase the neuromuscular blocking activities of Tubocurarine.
Aclidinium Physostigmine may increase the neuromuscular blocking activities of Aclidinium.
Butyrylthiocholine Physostigmine may increase the neuromuscular blocking activities of Butyrylthiocholine.
Oxybuprocaine Physostigmine may increase the neuromuscular blocking activities of Oxybuprocaine.
Benzonatate Physostigmine may increase the neuromuscular blocking activities of Benzonatate.
Succinylcholine The metabolism of Succinylcholine can be decreased when combined with Physostigmine.
Tramadol The therapeutic efficacy of Tramadol can be decreased when used in combination with Physostigmine.
Trospium The therapeutic efficacy of Trospium can be decreased when used in combination with Physostigmine.
Oxyphenonium The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Physostigmine.
Butabarbital The therapeutic efficacy of Butabarbital can be decreased when used in combination with Physostigmine.
Butalbital The therapeutic efficacy of Butalbital can be decreased when used in combination with Physostigmine.
Benzatropine The therapeutic efficacy of Benzatropine can be decreased when used in combination with Physostigmine.
Ziprasidone The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Physostigmine.
Disopyramide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Physostigmine.
Talbutal The therapeutic efficacy of Talbutal can be decreased when used in combination with Physostigmine.
Pentobarbital The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Physostigmine.
Amitriptyline The therapeutic efficacy of Amitriptyline can be decreased when used in combination with Physostigmine.
Ipratropium The therapeutic efficacy of Ipratropium can be decreased when used in combination with Physostigmine.
Methadone The therapeutic efficacy of Methadone can be decreased when used in combination with Physostigmine.
Olanzapine The therapeutic efficacy of Olanzapine can be decreased when used in combination with Physostigmine.
Metixene The therapeutic efficacy of Metixene can be decreased when used in combination with Physostigmine.
Terfenadine The therapeutic efficacy of Terfenadine can be decreased when used in combination with Physostigmine.
Buclizine The therapeutic efficacy of Buclizine can be decreased when used in combination with Physostigmine.
Clozapine The therapeutic efficacy of Clozapine can be decreased when used in combination with Physostigmine.
Doxylamine The therapeutic efficacy of Doxylamine can be decreased when used in combination with Physostigmine.
Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Physostigmine.
Oxyphencyclimine The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Physostigmine.
Procyclidine The therapeutic efficacy of Procyclidine can be decreased when used in combination with Physostigmine.
Profenamine The therapeutic efficacy of Profenamine can be decreased when used in combination with Physostigmine.
Secobarbital The therapeutic efficacy of Secobarbital can be decreased when used in combination with Physostigmine.
Promazine The therapeutic efficacy of Promazine can be decreased when used in combination with Physostigmine.
Hyoscyamine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Physostigmine.
Cyproheptadine The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Physostigmine.
Imipramine The therapeutic efficacy of Imipramine can be decreased when used in combination with Physostigmine.
Methscopolamine bromide The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Physostigmine.
Metharbital The therapeutic efficacy of Metharbital can be decreased when used in combination with Physostigmine.
Fluoxetine The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Physostigmine.
Chlorpromazine The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Physostigmine.
Darifenacin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Physostigmine.
Tridihexethyl The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Physostigmine.
Triflupromazine The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Physostigmine.
Dextromethorphan The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Physostigmine.
Anisotropine methylbromide The therapeutic efficacy of Anisotropine methylbromide can be decreased when used in combination with Physostigmine.
Nortriptyline The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Physostigmine.
Amoxapine The therapeutic efficacy of Amoxapine can be decreased when used in combination with Physostigmine.
Atropine The therapeutic efficacy of Atropine can be decreased when used in combination with Physostigmine.
Thiopental The therapeutic efficacy of Thiopental can be decreased when used in combination with Physostigmine.
Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Physostigmine.
Mecamylamine The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Physostigmine.
Pirenzepine The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Physostigmine.
Paroxetine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Physostigmine.
Homatropine methylbromide The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Physostigmine.
Scopolamine The therapeutic efficacy of Scopolamine can be decreased when used in combination with Physostigmine.
Isoflurane The therapeutic efficacy of Isoflurane can be decreased when used in combination with Physostigmine.
Benzquinamide The therapeutic efficacy of Benzquinamide can be decreased when used in combination with Physostigmine.
Clidinium The therapeutic efficacy of Clidinium can be decreased when used in combination with Physostigmine.
Propiomazine The therapeutic efficacy of Propiomazine can be decreased when used in combination with Physostigmine.
Propantheline The therapeutic efficacy of Propantheline can be decreased when used in combination with Physostigmine.
Primidone The therapeutic efficacy of Primidone can be decreased when used in combination with Physostigmine.
Dicyclomine The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Physostigmine.
Biperiden The therapeutic efficacy of Biperiden can be decreased when used in combination with Physostigmine.
Brompheniramine The therapeutic efficacy of Brompheniramine can be decreased when used in combination with Physostigmine.
Methylphenobarbital The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Physostigmine.
Quinidine The therapeutic efficacy of Quinidine can be decreased when used in combination with Physostigmine.
Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Physostigmine.
Maprotiline The therapeutic efficacy of Maprotiline can be decreased when used in combination with Physostigmine.
Methantheline The therapeutic efficacy of Methantheline can be decreased when used in combination with Physostigmine.
Hexafluronium The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Physostigmine.
Cycrimine The therapeutic efficacy of Cycrimine can be decreased when used in combination with Physostigmine.
Desloratadine The therapeutic efficacy of Desloratadine can be decreased when used in combination with Physostigmine.
Glycopyrronium The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Physostigmine.
Tolterodine The therapeutic efficacy of Tolterodine can be decreased when used in combination with Physostigmine.
Oxybutynin The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Physostigmine.
Promethazine The therapeutic efficacy of Promethazine can be decreased when used in combination with Physostigmine.
Diphenhydramine The therapeutic efficacy of Diphenhydramine can be decreased when used in combination with Physostigmine.
Pentolinium The therapeutic efficacy of Pentolinium can be decreased when used in combination with Physostigmine.
Doxepin The therapeutic efficacy of Doxepin can be decreased when used in combination with Physostigmine.
Flavoxate The therapeutic efficacy of Flavoxate can be decreased when used in combination with Physostigmine.
Desipramine The therapeutic efficacy of Desipramine can be decreased when used in combination with Physostigmine.
Orphenadrine The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Physostigmine.
Phenobarbital The therapeutic efficacy of Phenobarbital can be decreased when used in combination with Physostigmine.
Escitalopram The therapeutic efficacy of Escitalopram can be decreased when used in combination with Physostigmine.
Quetiapine The therapeutic efficacy of Quetiapine can be decreased when used in combination with Physostigmine.
Levacetylmethadol The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Physostigmine.
Diphenidol The therapeutic efficacy of Diphenidol can be decreased when used in combination with Physostigmine.
Aripiprazole The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Physostigmine.
Chlorprothixene The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Physostigmine.

Target Protein

Acetylcholinesterase ACHE
Neuronal acetylcholine receptor subunit alpha-4 CHRNA4
Neuronal acetylcholine receptor subunit beta-2 CHRNB2

Referensi & Sumber

Synthesis reference: Edward J. Glamkowski, Barbara E. Kurys, "4- and 6-carbamates related to physostigmine and intermediates for the preparation thereof." U.S. Patent US5081117, issued September, 1978.

Contoh Produk & Brand

Produk: 9 • International brands: 1
Produk
  • Anticholium
    Injection • 0.4 mg/1mL • Intravenous • US
  • Antilirium Inj 1mg/ml
    Liquid • 1 mg / mL • Intramuscular; Intravenous • Canada • Approved
  • Physostigmine Salicylate
    Injection • 1 mg/1mL • Intravenous • US
  • Physostigmine Salicylate
    Injection • 1 mg/1mL • Intravenous • US
  • Physostigmine Salicylate
    Injection • 1 mg/1mL • Intravenous • US
  • Physostigmine Salicylate
    Injection • 1 mg/1mL • Intravenous • US
  • Physostigmine Salicylate
    Injection • 1 mg/1mL • Intravenous • US
  • Physostigmine Salicylate
    Injection • 1 mg/1mL • Intravenous • US
Menampilkan 8 dari 9 produk.
International Brands
  • Antilirium

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul